bioAffinity Expands CyPath Lung Test to Bronchoscopy Samples in BAMC Study
Event summary
- bioAffinity Technologies partners with Brooke Army Medical Center to validate CyPath Lung test on sputum samples from tracheal/bronchial suctioning.
- Study aims to enroll 30-50 patients, with results expected by mid-2026.
- Current CyPath Lung protocol requires at-home sputum collection; new study expands to clinic-based suction samples.
- Bronchoscopy market valued at $700-920M annually in the U.S., with 500,000 procedures performed yearly.
The big picture
The study aligns with the growing demand for noninvasive, early-detection tools in lung cancer diagnostics. By validating CyPath Lung's use with bronchoscopy samples, bioAffinity aims to tap into a $700-920M market, leveraging existing clinical procedures to improve diagnostic efficiency. Success could position the test as a complementary tool in managing indeterminate lung nodules, a key challenge in pulmonary care.
What we're watching
- Clinical Validation
- Whether the study confirms CyPath Lung's effectiveness with suctioned sputum samples, potentially broadening its diagnostic applications.
- Market Expansion
- The pace at which bioAffinity can integrate bronchoscopy-collected samples into routine lung cancer screening protocols.
- Competitive Positioning
- How this expansion affects bioAffinity's standing against other early lung cancer detection technologies.
Related topics